[Drug therapy of hyperlipidemia. Current status in Germany].

Abstract

BACKGROUND:

Hyperlipidemia is an important, maybe the most important, risk factor for coronary artery disease (CAD). Therefore lowering elevated cholesterol is crucial for primary and secondary prevention. Dietary treatment but also drug therapy is frequently used to lower cholesterol in our days.

STATINS:

Drug therapy with statins has shown to be beneficial in clinical studies. Patients at a high risk for CAD will benefit mostly of drug treatment with a statin and in one out of 13 high-risk patients statin treatment will prevent one serious cardiovascular event [NNT (number needed to treat) = 13]. This is the reason for the success story of statins in the last decade. In Germany more than 700 million defined daily doses of lipid-lowering drugs are prescribed per year, which is sufficient for continuous treatment of 1.9 million patients. However, the broad use of statins came along with some thoughtlessness towards side effects. Safety laboratory values were not determined, contraindications were not considered to be serious enough and the lack of clinical endpoint studies was neglected. In addition there was an attempt to disregulate statins as "over the counter drugs" in the US--an attempt which was stopped by the intervention of the FDA. This practice ended in a series of severe side effects and led to the withdrawal of cerivastatin, a new statin from the market. If this will influence the drug treatment of hyperlipidemia needs to be seen.

• Authors: J R Schaefer
• Journal: Herz (Herz) Vol. 26 Issue 8 Pg. 507-12 (Dec 2001) ISSN: 0340-9937 [Print] Germany
• Vernacular Title: Medikamentöse Therapie der Hyperlipidämie. Aktuelle Lage in Deutschland.
• PMID: 11820153 (Publication Type: English Abstract, Journal Article)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Adverse Drug Reaction Reporting Systems
• Combined Modality Therapy
• Coronary Artery Disease (drug therapy)
• Diet, Fat-Restricted
• Drug Interactions
• Germany
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
• Hypercholesterolemia (drug therapy)
• Hyperlipidemias (drug therapy)
• Treatment Outcome